Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Vorinostat × Other solid neoplasm × Clear all

Phase

Status

Completed 8 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 3 Lymphoid 3 Dermatologic 2 Thoracic 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Head & Neck 1 Breast 1

Conditions

Mesothelioma, Malignant 1 Mesothelioma 1

Interventions

Cisplatin 7 Pemetrexed 6 atezolizumab 5 Carboplatin 4 Paclitaxel 3 Leucovorin 3 Filgrastim 3 Etoposide 3 vistusertib 2 tislelizumab 2 Vincristine 2 Topotecan 2 Temozolomide 2 Tegafur 2 Sorafenib 2 Irinotecan 2 Immunoenzyme Techniques 2 Gemcitabine 2 Docetaxel 2 Cyclophosphamide 2 zirconium-89-trastuzumab 1 vandetanib 1 toripalimab 1 temsirolimus 1 tanespimycin 1 talazoparib 1 soblidotin 1 selinexor 1 sargramostim 1 roniciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01353482 2012-03-22

MESO-02

University College, London

Phase 1/2 Withdrawn

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡